TABLE 2.

Clinical trials on OAd-based cancer vaccines.

OAd name	Transgene	Indication	Combination therapy	Clinical trial number	Phase
ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)	CEA	Colon cancer Lung cancer Breast cancer	–	NCT01147965	I/II
		Neoplasms Prostate cancer Lung cancer Breast cancer Colon cancer	ETBX-061 (Ad5 [E1-, E2b-]-MUC-1) ETBX-051 (Ad5 [E1-, E2b-]-brachyury)	NCT03384316	I
Ad5-PSA	PSA	Hormone refractory prostate cancer	–	NCT00583024	II
ETBX-071 (Ad5 [E1-, E2b-]-PSA)		Metastatic castration-resistant prostate cancer	ETBX-061 (Ad5 [E1-, E2b-]-MUC-1) ETBX-051 (Ad5 [E1-, E2b-]-brachyury)	NCT03481816	I
Ad-MAGEA3	MAGE-A3	Advanced/metastatic solid tumor	MG1-MAGEA3	NCT02285816	I/II
		Non-small cell lung cancer	MG1-MAGEA3, pembrolizumab	NCT02879760	I/II